$ cat ./records/who-grants-prequalification-to-rts-s-mosquirix-enabling-global-pr-2022.txt
WHO grants prequalification to RTS,S/Mosquirix — enabling global procurement for malaria vaccination programmes
[RECORD.TXT] · cat --full
The World Health Organization granted prequalification status to RTS,S/Mosquirix — the Gates Foundation-funded malaria vaccine — in July 2022, nine months after its landmark broad-use recommendation. WHO prequalification is the stamp required for procurement by UNICEF, Gavi, CEPI, and international government health programmes: without it, countries cannot buy the vaccine through multilateral channels. The prequalification opened the pathway for large-scale manufacturing and distribution to the highest-burden malaria countries in sub-Saharan Africa, completing the regulatory journey from clinical trials to real-world deployment.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Pledged $1,000,003 to UNHCR for Ukrainian refugees fleeing Russia's invasion
Next →
Gates Foundation commits $276 million to accelerate malaria eradication amid rising drug and insecticide resistance
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.